Conference Coverage

Bladder cancer: Two chemoradiation therapy regimens on par for muscle-invasive disease

Publish date: February 10, 2018

 

AT THE GENITOURINARY CANCERS SYMPOSIUM

SOURCE: Coen, J. et al, 2018 Genitourinary Cancers Symposium, Abstract 408

Pages

Recommended Reading

Mutations linked to checkpoint inhibitor response in RCC
MDedge Hematology and Oncology
In Brazil, few patients get second- and third-line treatment for metastatic RCC
MDedge Hematology and Oncology
OS similar among mRCC patients enrolled in clinical trials across different geographic regions
MDedge Hematology and Oncology
Pembrolizumab plus SBRT shows promise for advanced solid tumors
MDedge Hematology and Oncology
Apalutamide wins big in SPARTAN prostate cancer trial
MDedge Hematology and Oncology
New model predicts survival in atezolizumab-treated advanced urothelial carcinoma
MDedge Hematology and Oncology
Atezolizumab-bevacizumab combo tops sunitinib as first-line therapy for RCC
MDedge Hematology and Oncology
FDA approves abiraterone acetate for metastatic high-risk CSPC
MDedge Hematology and Oncology
Adding docetaxel to hormone therapy for advanced prostate cancer nets QOL benefit
MDedge Hematology and Oncology
Adjuvant chemo halves DFS events in upper-tract urothelial cancer
MDedge Hematology and Oncology